Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) CEO Robert Blum sold 7,500 shares of the stock in a transaction on Monday, November 16th. The shares were sold at an average price of $53.53, for a total value of $401,475.00. Following the sale, the chief executive officer owned 278,544 shares in the company, valued at approximately $14,910,460.32. This trade represents a 2.62% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Cytokinetics Trading Down 0.6%
Shares of NASDAQ CYTK traded down $0.33 during trading on Wednesday, reaching $51.32. The company had a trading volume of 1,594,452 shares, compared to its average volume of 2,065,668. Cytokinetics, Incorporated has a twelve month low of $51.00 and a twelve month high of $88.31. The stock has a market capitalization of $7.15 billion, a PE ratio of -8.50 and a beta of 0.45. The stock has a 50-day moving average price of $62.79 and a two-hundred day moving average price of $69.60.
Cytokinetics (NASDAQ:CYTK – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The biopharmaceutical company reported ($1.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.43) by $0.06. The company had revenue of $47.56 million during the quarter, compared to analysts’ expectations of $41.88 million. The firm’s revenue was up 2356.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($2.55) earnings per share. On average, sell-side analysts predict that Cytokinetics, Incorporated will post -5.85 EPS for the current year.
Institutional Trading of Cytokinetics
Several institutional investors have recently made changes to their positions in CYTK. Handelsbanken Fonder AB increased its holdings in Cytokinetics by 63.8% in the 2nd quarter. Handelsbanken Fonder AB now owns 405,000 shares of the biopharmaceutical company’s stock valued at $34,502,000 after purchasing an additional 157,700 shares in the last quarter. Sanders Morris Harris LLC acquired a new position in shares of Cytokinetics during the third quarter worth about $1,549,000. Great Lakes Advisors LLC acquired a new position in shares of Cytokinetics during the second quarter worth about $1,960,000. Siren L.L.C. purchased a new stake in shares of Cytokinetics in the first quarter worth about $40,466,000. Finally, Seven Fleet Capital Management LP boosted its position in shares of Cytokinetics by 93.0% in the second quarter. Seven Fleet Capital Management LP now owns 118,240 shares of the biopharmaceutical company’s stock worth $10,073,000 after buying an additional 56,971 shares during the period.
Analyst Upgrades and Downgrades
Several equities research analysts have issued reports on CYTK shares. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Cytokinetics in a research note on Friday, September 11th. Morgan Stanley upgraded Cytokinetics from an “overweight” rating to a “buy” rating in a research report on Tuesday, September 1st. William Blair started coverage on Cytokinetics in a research report on Friday, October 16th. They set an “outperform” rating on the stock. Barclays raised their price target on Cytokinetics from $95.00 to $110.00 and gave the stock an “overweight” rating in a research note on Thursday, August 13th. Finally, HC Wainwright restated a “buy” rating and issued a $140.00 price target on shares of Cytokinetics in a report on Monday, October 19th. Nineteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $106.67.
Check Out Our Latest Stock Analysis on CYTK
About Cytokinetics
Cytokinetics is a biopharmaceutical company focused on discovering and developing medicines that target the biology of muscle function. Its research centers on therapies for conditions involving impaired cardiac muscle performance. The company’s work includes aficamten, a cardiac myosin inhibitor developed for hypertrophic cardiomyopathy, and other drug candidates designed to affect muscle contraction. Cytokinetics conducts research and clinical development through programs that may involve patients and collaborators in multiple countries.
Featured Stories
- Five stocks we like better than Cytokinetics
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Cytokinetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics and related companies with MarketBeat.com's FREE daily email newsletter.
